Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10103782 | Journal of the American College of Surgeons | 2005 | 10 Pages |
Abstract
LVI is an adverse prognostic factor for relapse and survival in node-negative patients treated with mastectomy and systemic therapy. LVI, in combination with age older than 50 years, premenopausal status, grade III histology, or estrogen receptor-negative disease, identified patient subsets with 7-year LRR risks of approximately 15% to 20%. Prospective research is required to define the role of adjuvant radiotherapy in these patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Pauline T. (FRCPC), Celina M. BS, MSc, Freddy BSc, MSc, Junella BSc, Hosam A. (FRCPC), Allen (FRCS), Ivo A. (FRCPC),